Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Special Report
Aust Covid Vaccine Tracker

Pharma in Focus provides the latest updated information on the frontrunner vaccines, and their potential for Australia.

COVID-19 Vaccine Frontrunners
Manufacturer Name Type Trial Phase Cost (USD) Australian access
Gamaleya Institute Sputnik 5 Recombinant viral vectored Approved (Russia) Unknown Unknown
Pfizer/BioNtech BNT162b2 mRNA  Phase 3 $39 (two-dose treatment) Global supply
Moderna mRNA-1273 mRNA Phase 3 $50-60 (two-dose treatment) Unknown
AstraZeneca/University of Oxford AZD1222 Recombinant viral vectored Phase 3 $4 Govt letter of intent
Sinopharm N/A Inactivated  Phase 3 $145 (two-dose treatment) Unknown
Sinovac CoronaVac Inactivated  Phase 3 Unknown Unknown
CanSino Biologics Ad5-nCoV Recombinant viral vectored Phase 2 Unknown Unknown
Janssen Ad26.COV2.S Recombinant Phase 1 $10 (one shot) Unknown
NovaVax NVX-CoV2373 Recombinant Phase 2 Unknown Potential (local trials)
Sanofi/GSK/Clover/Dynavax SCB-2019 Recombinant Phase 1 <$12/dose Potential (local trials)
CSL/UQ "molecular clamp" Recombinant Phase 1 Unknown Locally developed; government funding; due H2 2021
Vaxine CoVAX-19 Recombinant Phase 1 Unknown Locally developed; no gov funding for phase 2 trials
Serum Institute of India RBD SARS-CoV-2 HBsAG VLP Recombinant Phase 1  Unknown Potential (local trials)
Monash University N/A mRNA pre-clinical Unknown Locally developed

 Tiffany Walker

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Special Report
Aust Covid Vaccine Tracker
Live updates on frontrunners, local trials and deals
Approvals Action
Six pharmas add generics
Most copy PBS listed drugs
Top of the Hill
If only for a 2020 time machine
What would you do if you could start this year again?